128 related articles for article (PubMed ID: 35417384)
61. Survey of British pathologists' performance of mesothelioma post-mortems.
Goldstein R; Hasleton PS
Pathol Res Pract; 2010 Mar; 206(3):174-9. PubMed ID: 20092958
[TBL] [Abstract][Full Text] [Related]
62. Tumoral CD10 expression correlates with aggressive histology and prognosis in patients with malignant pleural mesothelioma.
Kadota K; Villena-Vargas J; Nitadori J; Sima CS; Jones DR; Travis WD; Adusumilli PS
Ann Surg Oncol; 2015 Sep; 22(9):3136-43. PubMed ID: 25608772
[TBL] [Abstract][Full Text] [Related]
63. Calretinin but not caveolin-1 correlates with tumour histology and survival in malignant mesothelioma.
Thapa B; Walkiewicz M; Murone C; Asadi K; Deb S; Barnett S; Knight S; Mitchell P; Liew D; Watkins DN; John T
Pathology; 2016 Dec; 48(7):660-665. PubMed ID: 27780599
[TBL] [Abstract][Full Text] [Related]
64. Melan A (A103) is not a marker of mesothelioma.
Ordóñez NG; Shen SS; Zenali M; Deavers MT
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
[TBL] [Abstract][Full Text] [Related]
65. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
[TBL] [Abstract][Full Text] [Related]
66. Breast cancer or metastasis? An unusual case of metastatic malignant pleural mesothelioma to the breast.
Framarino-dei-Malatesta M; Sammartino P; Derme M; Iannini I; Masselli G; Pecorella I
World J Surg Oncol; 2015 Feb; 13():79. PubMed ID: 25849448
[TBL] [Abstract][Full Text] [Related]
67. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
68. What's new in mesothelioma.
Ascoli V; Murer B; Nottegar A; Luchini C; Carella R; Calabrese F; Lunardi F; Cozzi I; Righi L
Pathologica; 2018 Mar; 110(1):12-28. PubMed ID: 30259910
[TBL] [Abstract][Full Text] [Related]
69. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
Capkova L; Koubkova L; Kodet R
Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
[TBL] [Abstract][Full Text] [Related]
70. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
71. Clinically Occult Diffuse Pleural Mesothelioma in Patients Presenting With Spontaneous Pneumothorax.
Fels Elliott DR; Konopka KE; Hrycaj SM; Lagisetty KH; Myers JL; Farver CF; Huang T
Am J Clin Pathol; 2023 Sep; 160(3):322-330. PubMed ID: 37256702
[TBL] [Abstract][Full Text] [Related]
72. Hypoxia affects in vitro growth of newly established cell lines from patients with malignant pleural mesothelioma.
Goudarzi H; Hida Y; Takano H; Teramae H; Iizasa H; Hamada J
Biomed Res; 2013 Feb; 34(1):13-21. PubMed ID: 23428976
[TBL] [Abstract][Full Text] [Related]
73. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
74. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
75. Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.
Carbone M; Shimizu D; Napolitano A; Tanji M; Pass HI; Yang H; Pastorino S
Oncotarget; 2016 Sep; 7(37):59314-59321. PubMed ID: 27447750
[TBL] [Abstract][Full Text] [Related]
76. [Clinicopathological characteristics and prognosis of malignant pleural mesothelioma].
Chen WH; Zhang XL; Dai HP; Tong ZH; Zhang YH; Jin ML
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Nov; 36(11):825-8. PubMed ID: 24507393
[TBL] [Abstract][Full Text] [Related]
77. Anti-cytokeratin 5/6: a positive marker for epithelioid mesothelioma.
Clover J; Oates J; Edwards C
Histopathology; 1997 Aug; 31(2):140-3. PubMed ID: 9279564
[TBL] [Abstract][Full Text] [Related]
78. Unusual intraparenchymal growth patterns of malignant pleural mesothelioma.
Nind NR; Attanoos RL; Gibbs AR
Histopathology; 2003 Feb; 42(2):150-5. PubMed ID: 12558747
[TBL] [Abstract][Full Text] [Related]
79. Sarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases.
Oramas DM; Zaleski M; Moran CA
Int J Surg Pathol; 2021 Dec; 29(8):820-825. PubMed ID: 33939493
[TBL] [Abstract][Full Text] [Related]
80. Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.
Padgett DM; Cathro HP; Wick MR; Mills SE
Am J Surg Pathol; 2008 Jan; 32(1):123-7. PubMed ID: 18162779
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]